The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
Open accessAbstract
Regulatory T cells (Tregs) are abundant in tumor tissues, raising a question of whether immunosuppressive tumor-infiltrating Tregs (TI-Tregs) can be selectively depleted or functionally attenuated to evoke effective anti-tumor immune responses by conventional T cells (Tconvs), without perturbing Treg-dependent immune homeostasis in healthy organs and causing autoimmunity. Here, we review current cancer immunotherapy strategies, including immune checkpoint blockade (ICB) antibodies against CTLA-4 and PD-1 and discuss their effects on TI-Tregs. We also discuss approaches that exploit differentially regulated molecules on the cell surface (e.g., CTLA-4) and intracellularly (e.g., T cell receptor signaling molecules) between TI-Tregs and Tconvs as well as their dependence on cytokines (e.g., IL-2) and metabolites (e.g., lactate). We envisage that targeting TI-Tregs could be effective as a monotherapy and/or when combined with ICB antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Self-citationFoxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Self-citationTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
Self-citationBagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
Collison, L. W., Workman, C. J., Kuo, T. T., Boyd, K., Wang, Y., Vignali, K. M., Cross, R., Sehy, D., Blumberg, R. S., & Vignali, D. A. A. (2007) · Nature · doi:10.1038/nature06306 · Cited by 2,066
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance
Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., & Sakaguchi, S. (2002) · Nature Immunology · doi:10.1038/ni759 · Cited by 1,729
Self-citationRegulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces
Rubtsov, Y. P., Rasmussen, J. P., Chi, E. Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W. R., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.017 · Cited by 1,586
Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
Self-citationSimpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see)
Klein, L., Kyewski, B., Allen, P. M., & Hogquist, K. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3667 · Cited by 1,383
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
Ohta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
Metabolic support of tumour-infiltrating regulatory T cells by lactic acid
Watson, M. J., Vignali, P. D. A., Mullett, S. J., Overacre-Delgoffe, A. E., Peralta, R. M., Grebinoski, S., Menk, A. V., Rittenhouse, N. L., DePeaux, K., Whetstone, R. D., et al. (2021) · Nature · doi:10.1038/s41586-020-03045-2 · Cited by 1,259
Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments
Angelin, A., Gil-de-Gómez, L., Dahiya, S., Jiao, J., Guo, L., Levine, M. H., Wang, Z., Quinn, W. J., Kopinski, P. K., Wang, L., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.018 · Cited by 1,246
Setoguchi, R., Hori, S., Takahashi, T., & Sakaguchi, S. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041982 · Cited by 1,235
Self-citationRegulatory T Cells and Human Disease
Sakaguchi, S., Mikami, N., Wing, J. B., Tanaka, A., Ichiyama, K., & Ohkura, N. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041717 · Cited by 1,120
Self-citationRegulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue, Y., & Nishikawa, H. (2019) · Cancer Science · doi:10.1111/cas.14069 · Cited by 1,041
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Kamada, T., Togashi, Y., Tay, C., Ha, D., Sasaki, A., Nakamura, Y., Sato, E., Fukuoka, S., Tada, Y., Tanaka, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1822001116 · Cited by 1,008
Self-citationShang, B., Liu, Y., Jiang, S.-J., & Liu, Y. (2015) · Scientific Reports · doi:10.1038/srep15179 · Cited by 985
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Kumagai, S., Koyama, S., Itahashi, K., Tanegashima, T., Lin, Y.-T., Togashi, Y., Kamada, T., Irie, T., Okumura, G., Kono, H., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.001 · Cited by 892
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Self-citationImmune dysregulation in human subjects with heterozygous germline mutations in CTLA4
Kuehn, H. S., Ouyang, W., Lo, B., Deenick, E. K., Niemela, J. E., Avery, D. T., Schickel, J.-N., Tran, D. Q., Stoddard, J., Zhang, Y., et al. (2014) · Science · doi:10.1126/science.1255904 · Cited by 848
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
Schubert, D., Bode, C., Kenefeck, R., Hou, T. Z., Wing, J. B., Kennedy, A., Bulashevska, A., Petersen, B.-S., Schäffer, A. A., Grüning, B. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3746 · Cited by 832
Self-citationExtrathymically generated regulatory T cells control mucosal TH2 inflammation
Josefowicz, S. Z., Niec, R. E., Kim, H. Y., Treuting, P., Chinen, T., Zheng, Y., Umetsu, D. T., & Rudensky, A. Y. (2012) · Nature · doi:10.1038/nature10772 · Cited by 822
Kumagai, S., Togashi, Y., Kamada, T., Sugiyama, E., Nishinakamura, H., Takeuchi, Y., Vitaly, K., Itahashi, K., Maeda, Y., Matsui, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0769-3 · Cited by 783
Ohkura, N., Hamaguchi, M., Morikawa, H., Sugimura, K., Tanaka, A., Ito, Y., Osaki, M., Tanaka, Y., Yamashita, R., Nakano, N., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.09.010 · Cited by 754
Self-citationMaj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733
Onishi, Y., Fehervari, Z., Yamaguchi, T., & Sakaguchi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711106105 · Cited by 716
Self-citationTerme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2325 · Cited by 684
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors
Wang, H., Franco, F., Tsui, Y.-C., Xie, X., Trefny, M. P., Zappasodi, R., Mohmood, S. R., Fernández-García, J., Tsai, C.-H., Schulze, I., et al. (2020) · Nature Immunology · doi:10.1038/s41590-019-0589-5 · Cited by 672
Cyclic adenosine monophosphate is a key component of regulatory T cell–mediated suppression
Bopp, T., Becker, C., Klein, M., Klein-Heßling, S., Palmetshofer, A., Serfling, E., Heib, V., Becker, M., Kubach, J., Schmitt, S., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062129 · Cited by 658
Sugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Katayama, I., Ezoe, S., Kanakura, Y., Sato, E., Fukumori, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316796110 · Cited by 627
Self-citationKantarjian, H. M., Shah, N. P., Cortes, J. E., Baccarani, M., Agarwal, M. B., Undurraga, M. S., Wang, J., Kassack Ipiña, J. J., Kim, D.-W., Ogura, M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-376087 · Cited by 610
Cretney, E., Xin, A., Shi, W., Minnich, M., Masson, F., Miasari, M., Belz, G. T., Smyth, G. K., Busslinger, M., Nutt, S. L., et al. (2011) · Nature Immunology · doi:10.1038/ni.2006 · Cited by 605
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582
Scurfin (FOXP3) Acts as a Repressor of Transcription and Regulates T Cell Activation
Schubert, L. A., Jeffery, E., Zhang, Y., Ramsdell, F., & Ziegler, S. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104521200 · Cited by 548
Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion
Sawant, D. V., Yano, H., Chikina, M., Zhang, Q., Liao, M., Liu, C., Callahan, D. J., Sun, Z., Sun, T., Tabib, T., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0346-9 · Cited by 543
Dietary antigens limit mucosal immunity by inducing regulatory T cells in the small intestine
Kim, K. S., Hong, S.-W., Han, D., Yi, J., Jung, J., Yang, B.-G., Lee, J. Y., Lee, M., & Surh, C. D. (2016) · Science · doi:10.1126/science.aac5560 · Cited by 541
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540
Continuous Activation of Autoreactive CD4+ CD25+ Regulatory T Cells in the Steady State
Fisson, S., Darrasse-Jèze, G., Litvinova, E., Septier, F., Klatzmann, D., Liblau, R., & Salomon, B. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030686 · Cited by 522
Xu, C., Sun, S., Johnson, T., Qi, R., Zhang, S., Zhang, J., & Yang, K. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109235 · Cited by 518
Tekguc, M., Wing, J. B., Osaki, M., Long, J., & Sakaguchi, S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023739118 · Cited by 490
Self-citationThe Intersection between Tumor Angiogenesis and Immune Suppression
Rahma, O. E., & Hodi, F. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1543 · Cited by 472
Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., & Sakaguchi, S. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050940 · Cited by 466
Self-citationTargeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Allard, B., Pommey, S., Smyth, M. J., & Stagg, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0545 · Cited by 458
Tan, M. C. B., Goedegebuure, P. S., Belt, B. A., Flaherty, B., Sankpal, N., Gillanders, W. E., Eberlein, T. J., Hsieh, C.-S., & Linehan, D. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1746 · Cited by 450
Lipid signalling enforces functional specialization of Treg cells in tumours
Lim, S. A., Wei, J., Nguyen, T.-L. M., Shi, H., Su, W., Palacios, G., Dhungana, Y., Chapman, N. M., Long, L., Saravia, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03235-6 · Cited by 426
Perrot, I., Michaud, H.-A., Giraudon-Paoli, M., Augier, S., Docquier, A., Gros, L., Courtois, R., Déjou, C., Jecko, D., Becquart, O., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.091 · Cited by 423
Arce Vargas, F., Furness, A. J. S., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M. H., Miranda Rota, E., Dahan, R., Georgiou, A., Sledzinska, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.013 · Cited by 418
Duhen, T., Duhen, R., Lanzavecchia, A., Sallusto, F., & Campbell, D. J. (2012) · Blood · doi:10.1182/blood-2011-11-392324 · Cited by 413
CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
Stagg, J., Divisekera, U., Duret, H., Sparwasser, T., Teng, M. W. L., Darcy, P. K., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4246 · Cited by 401
Berner, F., Bomze, D., Diem, S., Ali, O. H., Fässler, M., Ring, S., Niederer, R., Ackermann, C. J., Baumgaertner, P., Pikor, N., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0402 · Cited by 395
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
Zappasodi, R., Serganova, I., Cohen, I. J., Maeda, M., Shindo, M., Senbabaoglu, Y., Watson, M. J., Leftin, A., Maniyar, R., Verma, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03326-4 · Cited by 393
Sugiura, D., Maruhashi, T., Okazaki, I.-M., Shimizu, K., Maeda, T. K., Takemoto, T., & Okazaki, T. (2019) · Science · doi:10.1126/science.aav7062 · Cited by 386
Raud, B., Roy, D. G., Divakaruni, A. S., Tarasenko, T. N., Franke, R., Ma, E. H., Samborska, B., Hsieh, W. Y., Wong, A. H., Stüve, P., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.002 · Cited by 386
Zhao, Y., Lee, C. K., Lin, C.-H., Gassen, R. B., Xu, X., Huang, Z., Xiao, C., Bonorino, C., Lu, L.-F., Bui, J. D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.11.003 · Cited by 383
Krieg, C., Létourneau, S., Pantaleo, G., & Boyman, O. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002569107 · Cited by 380
Vstm3 is a member of the CD28 family and an important modulator of T‐cell function
Levin, S. D., Taft, D. W., Brandt, C. S., Bucher, C., Howard, E. D., Chadwick, E. M., Johnston, J., Hammond, A., Bontadelli, K., Ardourel, D., et al. (2011) · European Journal of Immunology · doi:10.1002/eji.201041136 · Cited by 356
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets
Saleh, R., & Elkord, E. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.022 · Cited by 352
Pacella, I., Procaccini, C., Focaccetti, C., Miacci, S., Timperi, E., Faicchia, D., Severa, M., Rizzo, F., Coccia, E. M., Bonacina, F., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720113115 · Cited by 344
Coffelt, S. B., Tal, A. O., Scholz, A., De Palma, M., Patel, S., Urbich, C., Biswas, S. K., Murdoch, C., Plate, K. H., Reiss, Y., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0012 · Cited by 343
Manzo, T., Prentice, B. M., Anderson, K. G., Raman, A., Schalck, A., Codreanu, G. S., Nava Lauson, C. B., Tiberti, S., Raimondi, A., Jones, M. A., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191920 · Cited by 342
Wojtukiewicz, M. Z., Rek, M. M., Karpowicz, K., Górska, M., Polityńska, B., Wojtukiewicz, A. M., Moniuszko, M., Radziwon, P., Tucker, S. C., & Honn, K. V. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09976-0 · Cited by 335
Vang, T., Torgersen, K. M., Sundvold, V., Saxena, M., Levy, F. O., Skålhegg, B. S., Hansson, V., Mustelin, T., & Taskén, K. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.4.497 · Cited by 330
Aire-Dependent Thymic Development of Tumor-Associated Regulatory T Cells
Malchow, S., Leventhal, D. S., Nishi, S., Fischer, B. I., Shen, L., Paner, G. P., Amit, A. S., Kang, C., Geddes, J. E., Allison, J. P., et al. (2013) · Science · doi:10.1126/science.1233913 · Cited by 328
Schenk, U., Frascoli, M., Proietti, M., Geffers, R., Traggiai, E., Buer, J., Ricordi, C., Westendorf, A. M., & Grassi, F. (2011) · Science Signaling · doi:10.1126/scisignal.2001270 · Cited by 286
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
Codarri Deak, L., Nicolini, V., Hashimoto, M., Karagianni, M., Schwalie, P. C., Lauener, L., Varypataki, E. M., Richard, M., Bommer, E., Sam, J., et al. (2022) · Nature · doi:10.1038/s41586-022-05192-0 · Cited by 280
Sun, X., Wu, Y., Gao, W., Enjyoji, K., Csizmadia, E., Müller, C. E., Murakami, T., & Robson, S. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.007 · Cited by 279
Schuler, P. J., Saze, Z., Hong, C.-S., Muller, L., Gillespie, D. G., Cheng, D., Harasymczuk, M., Mandapathil, M., Lang, S., Jackson, E. K., et al. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12354 · Cited by 277
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
Haradhvala, N. J., Leick, M. B., Maurer, K., Gohil, S. H., Larson, R. C., Yao, N., Gallagher, K. M. E., Katsis, K., Frigault, M. J., Southard, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01959-0 · Cited by 271
Emerging Functions of Regulatory T Cells in Tissue Homeostasis
Sharma, A., & Rudra, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00883 · Cited by 262
Cohen, A. D., Schaer, D. A., Liu, C., Li, Y., Hirschhorn-Cymmerman, D., Kim, S. C., Diab, A., Rizzuto, G., Duan, F., Perales, M. A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010436 · Cited by 261
PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
Tan, C. L., Kuchroo, J. R., Sage, P. T., Liang, D., Francisco, L. M., Buck, J., Thaker, Y. R., Zhang, Q., McArdel, S. L., Juneja, V. R., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20182232 · Cited by 258
Kumagai, S., Togashi, Y., Sakai, C., Kawazoe, A., Kawazu, M., Ueno, T., Sato, E., Kuwata, T., Kinoshita, T., Yamamoto, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.016 · Cited by 257
CCR8+FOXp3+Tregcells as master drivers of immune regulation
Barsheshet, Y., Wildbaum, G., Levy, E., Vitenshtein, A., Akinseye, C., Griggs, J., Lira, S. A., & Karin, N. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621280114 · Cited by 249
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
Good, Z., Spiegel, J. Y., Sahaf, B., Malipatlolla, M. B., Ehlinger, Z. J., Kurra, S., Desai, M. H., Reynolds, W. D., Wong Lin, A., Vandris, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01960-7 · Cited by 248
Kim, C. G., Jang, M., Kim, Y., Leem, G., Kim, K. H., Lee, H., Kim, T.-S., Choi, S. J., Kim, H.-D., Han, J. W., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aay0555 · Cited by 245
Legoux, F. P., Lim, J.-B., Cauley, A. W., Dikiy, S., Ertelt, J., Mariani, T. J., Sparwasser, T., Way, S. S., & Moon, J. J. (2015) · Immunity · doi:10.1016/j.immuni.2015.10.011 · Cited by 238
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
Ge, Z., Peppelenbosch, M. P., Sprengers, D., & Kwekkeboom, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.699895 · Cited by 231
Coffelt, S. B., Chen, Y.-Y., Muthana, M., Welford, A. F., Tal, A. O., Scholz, A., Plate, K. H., Reiss, Y., Murdoch, C., De Palma, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002802 · Cited by 220
Spangler, J. B., Tomala, J., Luca, V. C., Jude, K. M., Dong, S., Ring, A. M., Votavova, P., Pepper, M., Kovar, M., & Garcia, K. C. (2015) · Immunity · doi:10.1016/j.immuni.2015.04.015 · Cited by 217
Tada, Y., Togashi, Y., Kotani, D., Kuwata, T., Sato, E., Kawazoe, A., Doi, T., Wada, H., Nishikawa, H., & Shitara, K. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0403-1 · Cited by 214
Kidani, Y., Nogami, W., Yasumizu, Y., Kawashima, A., Tanaka, A., Sonoda, Y., Tona, Y., Nashiki, K., Matsumoto, R., Hagiwara, M., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2114282119 · Cited by 212
Self-citationVan Damme, H., Dombrecht, B., Kiss, M., Roose, H., Allen, E., Van Overmeire, E., Kancheva, D., Martens, L., Murgaski, A., Bardet, P. M. R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001749 · Cited by 205
Ha, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing, J. B., Lim, E. L., Teng, K. W. W., Adeegbe, D., Newell, E. W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812186116 · Cited by 205
Self-citationSolomon, I., Amann, M., Goubier, A., Arce Vargas, F., Zervas, D., Qing, C., Henry, J. Y., Ghorani, E., Akarca, A. U., Marafioti, T., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00133-0 · Cited by 204
CD226 opposes TIGIT to disrupt Tregs in melanoma
Fourcade, J., Sun, Z., Chauvin, J.-M., Ka, M., Davar, D., Pagliano, O., Wang, H., Saada, S., Menna, C., Amin, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121157 · Cited by 199
Kudo, M. (2020) · Cancers · doi:10.3390/cancers12051089 · Cited by 197
Effects of interleukin-2 in immunostimulation and immunosuppression
Pol, J. G., Caudana, P., Paillet, J., Piaggio, E., & Kroemer, G. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191247 · Cited by 195
Amoozgar, Z., Kloepper, J., Ren, J., Tay, R. E., Kazer, S. W., Kiner, E., Krishnan, S., Posada, J. M., Ghosh, M., Mamessier, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22885-8 · Cited by 195
Kwilas, A. R., Ardiani, A., Donahue, R. N., Aftab, D. T., & Hodge, J. W. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0294-y · Cited by 192
Dovedi, S. J., Elder, M. J., Yang, C., Sitnikova, S. I., Irving, L., Hansen, A., Hair, J., Jones, D. C., Hasani, S., Wang, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1445 · Cited by 186
Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts
Bhattacharyya, S., Md Sakib Hossain, D., Mohanty, S., Sankar Sen, G., Chattopadhyay, S., Banerjee, S., Chakraborty, J., Das, K., Sarkar, D., Das, T., et al. (2010) · Cellular & Molecular Immunology · doi:10.1038/cmi.2010.11 · Cited by 186
The diversity and breadth of cancer cell fatty acid metabolism
Nagarajan, S. R., Butler, L. M., & Hoy, A. J. (2021) · Cancer & Metabolism · doi:10.1186/s40170-020-00237-2 · Cited by 185
Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment
Bourhis, M., Palle, J., Galy-Fauroux, I., & Terme, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.616837 · Cited by 184
Aswad, F., Kawamura, H., & Dennert, G. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.5.3075 · Cited by 183
PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface
Chaudhri, A., Xiao, Y., Klee, A. N., Wang, X., Zhu, B., & Freeman, G. J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0316 · Cited by 180
Cryo-EM Reveals Integrin-Mediated TGF-β Activation without Release from Latent TGF-β
Campbell, M. G., Cormier, A., Ito, S., Seed, R. I., Bondesson, A. J., Lou, J., Marks, J. D., Baron, J. L., Cheng, Y., & Nishimura, S. L. (2020) · Cell · doi:10.1016/j.cell.2019.12.030 · Cited by 178
Dodagatta-Marri, E., Meyer, D. S., Reeves, M. Q., Paniagua, R., To, M. D., Binnewies, M., Broz, M. L., Mori, H., Wu, D., Adoumie, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0493-9 · Cited by 177
Tumors establish resistance to immunotherapy by regulating T reg recruitment via CCR4
Marshall, L. A., Marubayashi, S., Jorapur, A., Jacobson, S., Zibinsky, M., Robles, O., Hu, D. X., Jackson, J. J., Pookot, D., Sanchez, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000764 · Cited by 169
Wei, X., Zhang, J., Gu, Q., Huang, M., Zhang, W., Guo, J., & Zhou, X. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.090 · Cited by 165
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Wu, X., Giobbie-Hurder, A., Liao, X., Connelly, C., Connolly, E. M., Li, J., Manos, M. P., Lawrence, D., McDermott, D., Severgnini, M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0206 · Cited by 164
Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models
Campbell, J. R., McDonald, B., Mesko, P. B., Siemers, N. O., Singh, P. B., Selby, M., Sproul, T. W., Korman, A. J., Vlach, L. M., Houser, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3585 · Cited by 151
Autocrine Adenosine Signaling Promotes Regulatory T Cell–Mediated Renal Protection
Kinsey, G. R., Huang, L., Jaworska, K., Khutsishvili, K., Becker, D. A., Ye, H., Lobo, P. I., & Okusa, M. D. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012010070 · Cited by 150
TCR- and CD28-Mediated Recruitment of Phosphodiesterase 4 to Lipid Rafts Potentiates TCR Signaling
Abrahamsen, H., Baillie, G. S., Ngai, J., Vang, T., Nika, K., Ruppelt, A., Mustelin, T., Zaccolo, M., Houslay, M. D., & Taskén, K. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.4847 · Cited by 143
VEGFR2 is selectively expressed by FOXP3high CD4+ Treg
Suzuki, H. Y., Onishi, H., 和田, 純., Yamasaki, A., Tanaka, H., Nakano, K., Morisaki, T., & Katano, M. (2009) · European Journal of Immunology · doi:10.1002/eji.200939887 · Cited by 136
Zhang, Y., Maksimovic, J., Naselli, G., Qian, J., Chopin, M., Blewitt, M. E., Oshlack, A., & Harrison, L. C. (2013) · Blood · doi:10.1182/blood-2013-02-481788 · Cited by 135
Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells
Nishikawa, H., Kato, T., Tawara, I., Saito, K., Ikeda, H., Kuribayashi, K., Allen, P. M., Schreiber, R. D., Sakaguchi, S., Old, L. J., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041959 · Cited by 130
Self-citationGARP: a key receptor controlling FOXP3 in human regulatory T cells
Probst‐Kepper, M., Geffers, R., Kröger, A., Viegas, N., Erck, C., Hecht, H., Lünsdorf, H., Roubin, R., Moharregh-Khiabani, D., Wagner, K., et al. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00782.x · Cited by 127
Mahne, A. E., Mauze, S., Joyce-Shaikh, B., Xia, J., Bowman, E. P., Beebe, A. M., Cua, D. J., & JAIN, R. K. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0797 · Cited by 127
Campbell, C., Dikiy, S., Bhattarai, S. K., Chinen, T., Matheis, F., Calafiore, M., Hoyos, B. E., Hanash, A. M., Mucida, D., Bucci, V., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.013 · Cited by 121
Targeting VEGF signalling via the neuropilin co-receptor
Djordjević, S., & Driscoll, P. C. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.11.013 · Cited by 118
CCR4 as a Therapeutic Target for Cancer Immunotherapy
Yoshie, O. (2021) · Cancers · doi:10.3390/cancers13215542 · Cited by 116
Modulation of T reg cells/ T effector function by GITR signaling is context–dependent
Ephrem, A., Epstein, A. L., Stephens, G. L., Thornton, A. M., Glass, D. D., & Shevach, E. M. (2013) · European Journal of Immunology · doi:10.1002/eji.201343451 · Cited by 115
Perry, J. A., Shallberg, L. A., Clark, J. T., Gullicksrud, J. A., DeLong, J. H., Douglas, B. B., Hart, A. P., Lanzar, Z. R., O’Dea, K. M., Konradt, C., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01170-w · Cited by 114
Affinity for self antigen selects Treg cells with distinct functional properties
Wyss, L., Stadinski, B. D., King, C. G., Schallenberg, S., McCarthy, N. I., Lee, J. Y., Kretschmer, K., Terracciano, L., Anderson, G., Surh, C. D., et al. (2016) · Nature Immunology · doi:10.1038/ni.3522 · Cited by 113
Toomer, K. H., Lui, J. B., Altman, N. H., Ban, Y. J., Chen, X. X., & Malek, T. R. (2019) · Nature Communications · doi:10.1038/s41467-019-08960-1 · Cited by 111
Ehrentraut, H., Westrich, J. A., Eltzschig, H. K., & Clambey, E. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032416 · Cited by 107
PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity
Sugiura, D., Okazaki, I., Maeda, T. K., Maruhashi, T., Shimizu, K., Arakaki, R., Takemoto, T., Ishimaru, N., & Okazaki, T. (2022) · Nature Immunology · doi:10.1038/s41590-021-01125-7 · Cited by 105
Edwards, J. P., Fujii, H., Zhou, A. X., Creemers, J. W. M., Unutmaz, D., & Shevach, E. M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300199 · Cited by 98
Whiteside, S. K., Grant, F. M., Győri, D., Conti, A. G., Imianowski, C. J., Kuo, P., Nasrallah, R., Sadiyah, F., Lira, S. A., Tacke, F., et al. (2021) · Immunology · doi:10.1111/imm.13337 · Cited by 97
Ren, Z., Zhang, A., Sun, Z., Liang, Y., Ye, J., Qiao, J., Li, B., & Fu, Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153604 · Cited by 97
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
Tanaka, A., Nishikawa, H., Noguchi, S., Sugiyama, D., Morikawa, H., Takeuchi, Y., Ha, D., Shigeta, N., Kitawaki, T., Maeda, Y., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191009 · Cited by 96
Self-citationThe Role of GITR/GITRL Interaction in Autoimmune Diseases
Tian, J., Zhang, B., Rui, K., & Wang, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.588682 · Cited by 92
Gaggero, S., Martínez‐Fábregas, J., Cozzani, A., Fyfe, P. K., Leprohon, M., Yang, J., Thomasen, F. E., Winkelmann, H., Magnez, R., Conti, A. G., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.ade5686 · Cited by 91
Kim, M. J., Kim, K., Park, H. J., Kim, G.-R., Hong, K. H., Oh, J. H., Son, J., Park, D. J., Kim, D., Choi, J.-M., et al. (2023) · Nature Immunology · doi:10.1038/s41590-022-01373-1 · Cited by 90
Homeostasis and transitional activation of regulatory T cells require c-Myc
Saravia, J., Zeng, H., Dhungana, Y., Blanco, D. B., Nguyen, T.-L. M., Chapman, N. M., Wang, Y., Kanneganti, A., Liu, S., Raynor, J. L., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaw6443 · Cited by 88
Cyclic AMP Represents a Crucial Component of Treg Cell-Mediated Immune Regulation
Klein, M., & Bopp, T. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00315 · Cited by 84
Rueda, C. M., Jackson, C. M., & Chougnet, C. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00216 · Cited by 78
González-Navajas, J. M., Fan, D. D., Yang, S., Yang, F. M., Lozano‐Ruiz, B., Shen, L., & Lee, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.625783 · Cited by 78
Sanseviero, E., O’Brien, E. M., Karras, J. R., Shabaneh, T. B., Aksoy, B. A., Xu, W., Zheng, C., Yin, X., Xu, X., Karakousis, G. C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0386 · Cited by 75
Preillon, J., Cuende, J., Rabolli, V., Garnero, L., Mercier, M., Wald, N., Pappalardo, A., Denies, S., Jamart, D., Michaux, A.-C., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0464 · Cited by 75
Lee, D. J., & Taylor, A. W. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300182 · Cited by 69
Chan, S., Belmar, N. A., Ho, S., Rogers, B. M., Stickler, M. M., Graham, M., Lee, E., Tran, N., Zhang, D., Gupta, P., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00334-9 · Cited by 67
Tanoue, T., & Honda, K. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.11.009 · Cited by 63
Weaver, J. D., Stack, E. C., Buggé, J. A., Hu, C., McGrath, L. L., Mueller, A., Wong, M., Klebanov, B., Rahman, T., Kaufman, R., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2141007 · Cited by 62
Chen, F., Xu, Y., Chen, Y., & Shan, S. (2020) · Cancer Medicine · doi:10.1002/cam4.2976 · Cited by 58
Medina, C. B., Chiu, Y., Stremska, M. E., Lucas, C. D., Poon, I. K. H., Tung, K. S. K., Elliott, M. R., Desai, B. N., Lorenz, U. M., Bayliss, D. A., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.014 · Cited by 57
Berezhnoy, A., Sumrow, B. J., Stahl, K., Shah, K., Liu, D., Li, J., Hao, S.-S., De Costa, A., Kaul, S., Bendell, J., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100163 · Cited by 56
Vila-Caballer, M., González, J. M., Zorita, V., Nabah, Y. N. A., Silvestre-Roig, C., Monte-Monge, A. D., Molina-Sánchez, P., Ait‐Oufella, H., Andrés‐Manzano, M. J., Sanz, M., et al. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.05.009 · Cited by 54
Gan, X., Shan, Q., Li, H., Janssens, R., Shen, Y., He, Y., Chen, F., van Haperen, R., Drabek, D., Li, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200879119 · Cited by 54
Han, Z., Dong, Y., Lu, J., Yang, F., Zheng, Y., & Yang, H. (2021) · American Journal of Cancer Research · Cited by 52
Wakiyama, H., Kato, T., Furusawa, A., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0041 · Cited by 49
de Oliveira, C. E., Gasparoto, T. H., Pinheiro, C. R., Amôr, N. G., Nogueira, M. R. S., Kaneno, R., Garlet, G. P., Lara, V. S., Silva, J. S., Cavassani, K. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0341 · Cited by 47
Roles of Regulatory T Cell-Derived Extracellular Vesicles in Human Diseases
Lin, C., Guo, J., & Jia, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911206 · Cited by 47
Suzuki, S., Ogawa, T., Sano, R., Takahara, T., Inukai, D., Satou, A., Tsuchida, H., Yoshikawa, K., Ueda, R., & Tsuzuki, T. (2020) · Cancer Science · doi:10.1111/cas.14422 · Cited by 46
Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation
Jin, G.-H., Hirano, T., & Murakami, M. (2008) · International Immunology · doi:10.1093/intimm/dxn036 · Cited by 45
Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity
Burton, E. M., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0257 · Cited by 40
Taskén, K. (2006) · Frontiers in bioscience · doi:10.2741/2022 · Cited by 38
Zhang, T., Sun, J., Li, J., Zhao, Y., Zhang, T., Yang, R., & Ma, X. (2021) · BMC Cancer · doi:10.1186/s12885-021-08363-w · Cited by 33
A tumor-specific mechanism of T reg enrichment mediated by the integrin αvβ8
Seed, R., Kobayashi, K., Ito, S., Takasaka, N., Cormier, A., Jespersen, J. M., Publicover, J., Trilok, S., Combes, A. J., Chew, N. W., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf0558 · Cited by 32
The Curcumin Analog GO-Y030 Controls the Generation and Stability of Regulatory T Cells
Maruyama, T., Kobayashi, S., Nakatsukasa, H., Moritoki, Y., Taguchi, D., Sunagawa, Y., Morimoto, T., Asao, A., Jin, W., Owada, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687669 · Cited by 30
Yi, G., Guo, S., Liu, W., Wang, H., Liu, R., Tsun, A., Jin, G. Y., & Li, B. (2018) · 中国科学通报:英文版 · doi:10.1016/j.scib.2018.05.028 · Cited by 29
Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy
Sato, Y., Casson, C. N., Matsuda, A., Kim, J. I., Shi, J. Q., Iwasaki, S., Chen, S. E., Modrell, B., Chan, C., Tavares, D., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03170-z · Cited by 29
Construction of a T cell receptor signaling range for spontaneous development of autoimmune disease
Tanaka, A., Maeda, S., Nomura, T., Llamas-Covarrubias, M. A., Tanaka, S., Lin, J., Lim, E. L., Morikawa, H., Kitagawa, Y., Akizuki, S., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220386 · Cited by 29
Self-citationAnti–PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells
Vick, S. C., Kolupaev, O., Perou, C. M., & Serody, J. S. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001334 · Cited by 28
Connexin 43 Signaling Enhances the Generation of Foxp3+ Regulatory T Cells
Kuczma, M., Lee, J. R., & Kraj, P. J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003785 · Cited by 27
Robles, O., Jackson, J. J., Marshall, L. A., Talay, O., Chian, D., Cutler, G., Diokno, R., Hu, D. X., Jacobson, S., Karbarz, E., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00988 · Cited by 27
SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling
Zhao, B. L., Gong, W., Ma, A., Chen, J., Velegraki, M., Dong, H., Liu, Z., Wang, L., Okimoto, T., Jones, D. M., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01326-8 · Cited by 27
Ishikura, N., Sugimoto, M., Yorozu, K., Kurasawa, M., & Kondoh, O. (2021) · Oncology Reports · doi:10.3892/or.2021.8247 · Cited by 25
Eschborn, M., Weigmann, B., Reißig, S., Waisman, A., Saloga, J., & Bellinghausen, I. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.04.020 · Cited by 24
Programmed Cell Death-1 Pathway Deficiency Enhances Autoimmunity Leading to Dacryoadenitis of Mice
Sakurai, Y., Usui, Y., Hattori, T., Takeuchi, M., Takayama, K., Karasawa, Y., Nishio, Y., Yamakawa, N., Saitoh, D., Gotô, H., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.02.014 · Cited by 11
High-level of intratumoral GITR+ CD4 T cells associate with poor prognosis in gastric cancer
Ke, S., Xie, F., Guo, Y., Chen, J., Wang, Z., Yu, Y., Geng, H., Xu, D., Liu, X., Xia, X., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105529 · Cited by 11
Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
Wei, Z., & Zhang, Y. (2022) · Cells · doi:10.3390/cells11111758 · Cited by 10
Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody
van Elsas, M. J., van der Schoot, J. M. S., Bartels, A., Steuten, K., van Dalen, D., Wijfjes, Z., Figdor, C. G., van Hall, T., van der Burg, S. H., Verdoes, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158707 · Cited by 6
Cited by
Principles and therapeutic applications of adaptive immunity
Chi, H., Pepper, M., & Thomas, P. G. (2024) · Cell · doi:10.1016/j.cell.2024.03.037 · Cited by 330
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Molina-Arcas, M., & Downward, J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.012 · Cited by 152
Myojin, Y., Babaei, S., Trehan, R., Hoffman, C., Kedei, N., Ruf, B., Benmebarek, M.-R., Bauer, K. C., Huang, P., Ma, C., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334026 · Cited by 24
He, J., Xue, W., & Li, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s560983 · Cited by 16
Metadata
- Authors
- Tay, C., Tanaka, A., & Sakaguchi, S.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2023-03
- Volume
- 41
- Issue
- 3
- Pages
- 450-465
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W4324046205
- Cited by
- 580
- References
- 185
- FWCI
- 59.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.